ASP Isotopes Inc. disclosed a 15.1% beneficial ownership stake in ENDRA Life Sciences Inc., comprising common shares and pre-funded warrants. A proposed merger with Noble Africa LLC may grant ASP Isot
ASP Isotopes Inc. filed a Form 8K on October 2nd, indicating a significant corporate event. Specific details of the disclosure require reviewing the official filing.
ENDRA Life Sciences filed a Form S-4 registration statement to merge with Noble Africa, a subsidiary of ASP Isotopes. The deal aims to combine ASP's South African assets with a Nasdaq-listed entity pe
ENDRA filed a Form S-4 registration statement for its proposed merger with Noble Africa, a subsidiary of ASP Isotopes, incorporating material disclosures regarding Renergen and financial impacts.
ASP Isotopes director Robert John Andrew Ryan purchased 15,000 shares at an average price of $2.68, raising his direct holdings to 675,222 shares. The acquisition occurred across multiple transactions
ASP Isotopes Inc. director Robert John Andrew Ryan purchased 8,000 shares at an average price of $2.70 per share. The transaction was reported via Form 4, signaling positive insider sentiment.
ASP Isotopes Inc. financial overview on the Hannover Stock Exchange shows a closed market with no trades, presenting an early-stage report structure without detailed revenue figures.
Halper Sadeh LLC is investigating ASP Isotopes Inc. officers for potential fiduciary breaches, offering free consultations to long-term shareholders seeking corporate governance reforms.
ASP Isotopes director Todd Wider filed notice to sell 200,000 shares worth $590,000 via J.P. Morgan, following two prior sales in June 2026.
At its inaugural Capital Markets Day, ASP Isotopes outlined a strategy targeting $300 million EBITDA by 2031 through nuclear medicine, helium, and LNG production, with commercial shipments commencing
ASP Isotopes targets $300 million EBITDA by 2031 following its inaugural Capital Markets Day, driven by liquid helium, radiopharmacy, and stable isotope commercialization. The company also announced p
ASP Isotopes Inc. COO Robert Ainscow sold 8,438 shares at $4.292 per share under a Rule 10b5-1 plan to cover tax withholding obligations on vested restricted stock awards.
ASP Isotopes Inc. is exploring a nuclear fuel conversion pilot in Namibia via subsidiary QLE to strengthen global fuel-cycle capabilities. The project leverages Namibia's uranium production to transit
ASP Isotopes Inc. submitted a filing under Securities Act Rule 425 concerning prospectuses and communications related to ongoing business combination transactions.
ASP Isotopes Inc. plans to commence commercial helium production and expand stable isotope facilities, including Silicon-28 and Carbon-14, within six months. Initial shipments from its South African p
ASP Isotopes' subsidiary Tetra4 has begun commissioning its Phase 1 liquid helium plant in South Africa, targeting first commercial shipments by September 2026. The project is projected to generate ov
ENDRA Life Sciences announced that ASP Isotopes' partner, Tetra4, has initiated commissioning for the liquid helium plant at the Virginia Gas Project. This marks a significant operational milestone fo
ASP Isotopes Inc.'s subsidiary Renergen has commenced commissioning a liquid helium plant in South Africa to address global shortages. Commercial shipments are anticipated by September 2026, with Phas
ASP Isotopes Inc. announced its subsidiary Quantum Leap Energy is evaluating metal conversion opportunities in Namibia. An environmental assessment is underway for a proposed pilot-scale hydrofluorina
ASP Isotopes Inc. submitted a Form 8K filing on August 18, leading to a 3.98% decline in its common stock price as reported by Investing.com.
ASP Isotopes reported a quarterly loss of $0.28 per share, missing analyst estimates by $0.11. Shares fell 0.2% to $4.27 following the release, while insiders sold over $2 million worth of stock.
ASP Isotopes Inc. reported quarterly revenue of $5.1 million and narrowed its net loss to $34.0 million following the acquisition of Renergen. The deal diversified the company into helium and LNG sect
ASP Isotopes secured a five-year take-or-pay LNG contract with a South African food processor for its Virginia Gas Project. The agreement covers 10% of Phase 1 capacity at over $16 per GJ, with produc
ASP Isotopes Inc. is set to release Q2 2026 earnings on August 14th, with analysts forecasting a $0.17 per share loss and $4.47 million revenue.
ASP Isotopes Inc. filed a Form 8K on August 6 according to Investing.com, though the announcement provided no further details regarding the specific contents of the filing.
ASP Isotopes Inc.'s subsidiary Tetra4 secured a five-year take-or-pay contract to supply LNG from South Africa's Virginia Gas Project to a food processor, covering 10% of Phase 1 capacity at over $16/
ASP Isotopes' subsidiary Tetra4 secured a five-year LNG supply contract to a domestic food processor via the Virginia Gas Project in South Africa, targeting commercial operations in Q3 2026 at over $1
ASP Isotopes will host investor meetings at the Citi Natural Resources Conference on August 13, 2026, discussing proposed merger transactions involving ENDRA, Renergen, and Noble Africa.
ASP Isotopes Inc. will host investor meetings at Citi's 2026 Natural Resources Conference, showcasing isotope enrichment technologies for critical materials and announcing a proposed merger with ENDRA
ASP Isotopes forecasts $14 million revenue for its PET Labs division by 2026, while helium production and isotope enrichment facilities near commercial launch. Subsidiary Renergen expects $27 million
ASP Isotopes reported over 50% organic revenue growth for its PET Labs segment in H1 2026, while isotope facilities and Renergen projects approach key milestones ahead of Q2 financial results.
ASP Isotopes reported 50% organic revenue growth in PET Labs and near-commercial production of Silicon-28 and Ytterbium-176. The company highlighted helium production plans amid global shortages while
ASP Isotopes Inc. will present at the Canaccord Genuity Growth Conference on August 12, 2026, led by CCO Viktor Petkov. The press release also highlighted proposed merger transactions with ENDRA, Rene
ASP Isotopes announced a live webcast of its Chief Commercial Officer's presentation at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The session will detail proprietary sepa
ASP Isotopes Inc received a valuation score of 8.28 within the Pharmaceuticals industry, with a P/E ratio of -1.73 indicating significant volatility against recent market levels.
ASP Isotopes Inc reported a 279.45% revenue increase to $4.18 million and 18.57% net profit growth, maintaining stable financial status despite limited disclosure on operational efficiency within the
ASP Isotopes Inc received a risk assessment score of 2.85, ranking 111th among 155 pharmaceutical companies. The report highlights high volatility with a beta of 3.41 and a 240-day maximum drawdown of
ASP Isotopes Inc. (NASDAQ: ASPI) announced a Capital Markets Day in London on September 8, 2026, to update investors on its portfolio and future plans. The invitation-only event aims to discuss progre
ASP Isotopes will host a Capital Markets Day in London on September 8, detailing strategies for nuclear medicine, electronic gases, and nuclear fuels alongside proposed merger transactions with ENDRA
ASP Isotopes Inc. announced a Capital Markets Day in London on September 8, 2026, featuring strategy updates on nuclear medicine, electronic gases, and nuclear fuels. The event includes a live webcast
ASP Isotopes Inc. will host a Capital Markets Day in London on September 8, 2026, offering insights into nuclear medicine, electronic gases, and nuclear fuels strategies via live webcast.
ASP Isotopes Inc reports no dividends distributed over the past five years. Current stock metrics include price, market cap, and P/E ratio alongside historical payout timelines.
ASP Isotopes Inc. shows mixed market signals with a 'Buy' analyst consensus and $10 price target, despite rising short interest and net insider selling.
Analysts recommend a Buy trend for ASP Isotopes Inc with an average price target of $13.00 and expected revenue of $4.47 million for the next quarter within the Pharmaceuticals industry.
ASP Isotopes Inc., an advanced materials firm producing isotopes for healthcare and nuclear fuels, saw shares fall over 45% despite significant revenue growth and a 'Buy' analyst rating.
ASP Isotopes Inc. filed a prospectus under Securities Act Rule 425 regarding communications connected to its business combination transactions.
ASP Isotopes Inc. will launch Phase I helium shipments in September from its South African facility, aiming to leverage severe global shortages and record prices. The project is backed by strategic fu
ASP Isotopes plans to merge with ENDRA Life Sciences to form Noble Africa, a helium and LNG platform leveraging Renergen's South African resources. Phase 1 production targets Q3 completion with shipme
ASP Isotopes partnered with Texas A&M to advance high-purity uranium hexafluoride production, aiming to improve efficiency and strengthen the U.S. nuclear fuel supply chain. The collaboration focuses
ASP Isotopes' subsidiary Quantum Leap Energy partnered with Texas A&M TEES to develop scalable domestic production of high-purity uranium hexafluoride (UF6). The project aims to improve efficiency, re
ChemBrief